Intercessor
Beloved of All
“Why does Novavax’s vaccine have so many fans?
Novavax’s protein-based vaccine uses a technology that’s been around for decades, and has long been used in flu shots and vaccinations in babies against hepatitis-B.
“Novavax’s vaccine offers something different; it is based on well-understood, protein-based technology that has been used for decades in vaccinations like flu, HPV and shingles,” said Silvia Taylor, Novavax’s senior vice president of global corporate affairs, in a January interview with Fortune.
As of March 6, 76.5% of the U.S. population had received at least one dose of a coronavirus vaccine, while 65.1% were fully vaccinated, according to the Mayo Clinic’s vaccination tracker.
The Novavax vaccine could help improve that number. In an interview with CNN late last year, Novavax CEO Stanley Erck said the “primary market” for his company’s vaccine was “people who have been hesitant to get other vaccines.”
Doctors seem to agree.
“It’s important to offer the choice,” Carina Rodriguez, chief of infectious diseases at the University of South Florida, told the Wall Street Journal. “Maybe it will not completely eliminate the issue of vaccine hesitancy but will help people who are not comfortable going with an mRNA vaccine.”
The U.S. is about to approve a fourth COVID vaccine that could be a silver bullet solution to the anti-vax crisis — FORTUNE
Novavax’s protein-based vaccine uses a technology that’s been around for decades, and has long been used in flu shots and vaccinations in babies against hepatitis-B.
“Novavax’s vaccine offers something different; it is based on well-understood, protein-based technology that has been used for decades in vaccinations like flu, HPV and shingles,” said Silvia Taylor, Novavax’s senior vice president of global corporate affairs, in a January interview with Fortune.
As of March 6, 76.5% of the U.S. population had received at least one dose of a coronavirus vaccine, while 65.1% were fully vaccinated, according to the Mayo Clinic’s vaccination tracker.
The Novavax vaccine could help improve that number. In an interview with CNN late last year, Novavax CEO Stanley Erck said the “primary market” for his company’s vaccine was “people who have been hesitant to get other vaccines.”
Doctors seem to agree.
“It’s important to offer the choice,” Carina Rodriguez, chief of infectious diseases at the University of South Florida, told the Wall Street Journal. “Maybe it will not completely eliminate the issue of vaccine hesitancy but will help people who are not comfortable going with an mRNA vaccine.”
The U.S. is about to approve a fourth COVID vaccine that could be a silver bullet solution to the anti-vax crisis — FORTUNE